thalidomide has been researched along with T-Cell Lymphoma in 14 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases." | 7.73 | Single-agent thalidomide induces response in T-cell lymphoma. ( Bilger, K; Bouabdallah, R; Damaj, G; Gastaut, JA; Mohty, M; Vey, N, 2005) |
| "Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL." | 5.39 | Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. ( Beckers, MM; Huls, G, 2013) |
| "Patients with recurrent and refractory T-cell lymphomas other than mycosis fungoides and untreated patients ineligible for combination chemotherapy were prescribed oral lenalidomide (25 mg daily) on Days 1 to 21 of each 28-day cycle until disease progression, death, or unacceptable toxicity." | 5.14 | Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. ( Belch, A; Chua, N; Dueck, G; Finch, D; Johnston, J; Prasad, A; Reiman, T; Stewart, D; van der Jagt, R; White, D, 2010) |
| " Thalidomide is an immunomodulatory drug with numerous properties that has proven effective in relapsed multiple myeloma and, to a lesser extent, in other hematologic diseases." | 3.73 | Single-agent thalidomide induces response in T-cell lymphoma. ( Bilger, K; Bouabdallah, R; Damaj, G; Gastaut, JA; Mohty, M; Vey, N, 2005) |
| "Lenalidomide even in lower dosed combined with steroids can induce complete responses in patients with refractory AITL." | 1.39 | Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide. ( Beckers, MM; Huls, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, W | 1 |
| Nelson, GM | 1 |
| Koch, R | 1 |
| Donovan, KA | 1 |
| Nowak, RP | 1 |
| Heavican-Foral, TB | 1 |
| Nirmal, AJ | 1 |
| Liu, H | 1 |
| Yang, L | 1 |
| Duffy, J | 1 |
| Powers, F | 1 |
| Stevenson, KE | 1 |
| Jones, MK | 1 |
| Ng, SY | 1 |
| Wu, G | 1 |
| Jain, S | 1 |
| Xu, R | 1 |
| Amaka, S | 1 |
| Trevisani, C | 1 |
| Donaldson, NL | 1 |
| Hagner, PR | 1 |
| de Leval, L | 1 |
| Gaulard, P | 1 |
| Iqbal, J | 1 |
| Thakurta, A | 1 |
| Fischer, ES | 1 |
| Adelman, K | 1 |
| Weinstock, DM | 1 |
| Grommes, C | 1 |
| Nayak, L | 1 |
| Tun, HW | 1 |
| Batchelor, TT | 1 |
| Broccoli, A | 1 |
| Pellegrini, C | 1 |
| Celli, M | 1 |
| Argnani, L | 1 |
| Agostinelli, C | 1 |
| Pileri, S | 1 |
| Zinzani, PL | 1 |
| Dickinson, M | 1 |
| Prince, HM | 1 |
| Chaoui, D | 1 |
| Bouallegue, S | 1 |
| Arakelyan, N | 1 |
| Genet, P | 1 |
| Aljijakli, A | 1 |
| Sutton, L | 1 |
| Duvic, M | 1 |
| Townsend, W | 1 |
| Johnson, RJ | 1 |
| Pottinger, BT | 1 |
| Counsell, N | 1 |
| Smith, P | 1 |
| Chadwick, H | 1 |
| Evans, K | 1 |
| Wickham, C | 1 |
| Rudin, CE | 1 |
| Huang, HY | 1 |
| Song, YQ | 1 |
| Zheng, W | 1 |
| Wang, XP | 1 |
| Xie, Y | 1 |
| Lin, NJ | 1 |
| Tu, MF | 1 |
| Zhang, C | 1 |
| Ping, LY | 1 |
| Liu, WP | 1 |
| Ying, ZT | 1 |
| Deng, LJ | 1 |
| Ding, N | 1 |
| Wu, M | 1 |
| Sun, YL | 1 |
| Du, TT | 1 |
| Leng, X | 1 |
| Zhu, J | 1 |
| Kwong, YL | 1 |
| Iannitto, E | 1 |
| Ferreri, AJ | 1 |
| Minardi, V | 1 |
| Tripodo, C | 1 |
| Kreipe, HH | 1 |
| Dueck, G | 1 |
| Chua, N | 1 |
| Prasad, A | 1 |
| Finch, D | 1 |
| Stewart, D | 1 |
| White, D | 1 |
| van der Jagt, R | 1 |
| Johnston, J | 1 |
| Belch, A | 1 |
| Reiman, T | 1 |
| Beckers, MM | 1 |
| Huls, G | 1 |
| Damaj, G | 1 |
| Bouabdallah, R | 1 |
| Vey, N | 1 |
| Bilger, K | 1 |
| Mohty, M | 1 |
| Gastaut, JA | 1 |
| Dogan, A | 1 |
| Ngu, LS | 1 |
| Ng, SH | 1 |
| Cervi, PL | 1 |
3 reviews available for thalidomide and T-Cell Lymphoma
| Article | Year |
|---|---|
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; | 2019 |
Emerging drugs for T-cell lymphoma.
Topics: Alemtuzumab; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Azepines; Brentuximab Ve | 2014 |
Angioimmunoblastic T-cell lymphoma.
Topics: B-Lymphocytes; CD4-Positive T-Lymphocytes; Cell Proliferation; Dendritic Cells; Epstein-Barr Virus I | 2008 |
2 trials available for thalidomide and T-Cell Lymphoma
| Article | Year |
|---|---|
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease P | 2016 |
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2010 |
9 other studies available for thalidomide and T-Cell Lymphoma
| Article | Year |
|---|---|
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
Topics: Drug Resistance, Neoplasm; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; L | 2022 |
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2014 |
Bortezomib, lenalidomide and dexamethasone (VRD) combination as salvage therapy in refractory angioimmunoblastic T cell lymphoma.
Topics: Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female | 2014 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic | 2015 |
[Clinical analysis of thalidomide in 36 untreated patients with T-cell lymphoma].
Topics: Humans; Lymphoma, T-Cell; Thalidomide; Treatment Outcome | 2016 |
Radiologic and molecular remission of follicular T cell lymphoma treated with lenalidomide.
Topics: Aged; Angiogenesis Inhibitors; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, T-Cell; Male; P | 2017 |
Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.
Topics: Antineoplastic Agents, Hormonal; Humans; Immunoblastic Lymphadenopathy; Lenalidomide; Lymphoma, T-Ce | 2013 |
Single-agent thalidomide induces response in T-cell lymphoma.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Lymphoma, T-Cell; Male; Middle Ag | 2005 |
Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide.
Topics: Aged; Antigens, CD; Female; Humans; Lymphoma, T-Cell; Thalidomide; Thorax; Tomography, X-Ray Compute | 2005 |